These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23778909)

  • 21. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
    Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
    Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer.
    Sayama C; Willsey M; Chintagumpala M; Brayton A; Briceño V; Ryan SL; Luerssen TG; Hwang SW; Jea A
    J Neurosurg Pediatr; 2015 Jul; 16(1):4-13. PubMed ID: 25860984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
    Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA
    Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Letter to the editor regarding "A critical review of recombinant human morphogenetic protein-2 trials in spine surgery: emerging safety concerns and lessons learned".
    Anderson PA
    Spine J; 2012 Apr; 12(4):356; author reply 356-7; discussion 357-9. PubMed ID: 22464143
    [No Abstract]   [Full Text] [Related]  

  • 25. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
    Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
    Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications.
    Malham GM; Parker RM; Ellis NJ; Blecher CM; Chow FY; Claydon MH
    J Neurosurg Spine; 2014 Dec; 21(6):851-60. PubMed ID: 25279655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reply to "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned".
    Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
    Spine J; 2011 Nov; 11(11):1082-3; author reply 1083-6. PubMed ID: 22078853
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned.
    Woo EJ
    Spine J; 2011 Aug; 11(8):804; author reply 804-5. PubMed ID: 21925424
    [No Abstract]   [Full Text] [Related]  

  • 29. Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery.
    Tannoury CA; An HS
    Spine J; 2014 Mar; 14(3):552-9. PubMed ID: 24412416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Too good to be true].
    Brox JI
    Tidsskr Nor Laegeforen; 2011 Nov; 131(22):2228-9. PubMed ID: 22085945
    [No Abstract]   [Full Text] [Related]  

  • 31. The Role of Bone Morphogenetic Proteins 2, 7, and 14 in Approaches for Intervertebral Disk Restoration.
    Belykh E; Giers M; Bardonova L; Theodore N; Preul M; Byvaltsev V
    World Neurosurg; 2015 Oct; 84(4):871-3. PubMed ID: 26299263
    [No Abstract]   [Full Text] [Related]  

  • 32. Ultra-low-dose recombinant human bone morphogenetic protein-2 for 3-level anterior cervical diskectomy and fusion.
    Pourtaheri S; Hwang K; Faloon M; Issa K; Mease SJ; Mangels D; Sinha K; Emami A
    Orthopedics; 2015 Apr; 38(4):241-5. PubMed ID: 25901613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stand-alone anterior lumbar interbody fusion for degenerative disc disease of the lumbar spine: results with a 2-year follow-up.
    Lammli J; Whitaker MC; Moskowitz A; Duong J; Dong F; Felts L; Konye G; Ablah E; Wooley P
    Spine (Phila Pa 1976); 2014 Jul; 39(15):E894-901. PubMed ID: 24825156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
    Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
    Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
    Chen NF; Smith ZA; Stiner E; Armin S; Sheikh H; Khoo LT
    J Neurosurg Spine; 2010 Jan; 12(1):40-6. PubMed ID: 20043763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent article by Shields et al titled "adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion".
    Bennett M; Reynolds AS; Dickerman RD
    Spine (Phila Pa 1976); 2006 Aug; 31(17):2029-30. PubMed ID: 16924224
    [No Abstract]   [Full Text] [Related]  

  • 37. rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys!
    Dickerman RD; Reynolds AS; Morgan BC; Tompkins J; Cattorini J; Bennett M
    Spine J; 2007; 7(4):508-9. PubMed ID: 17521966
    [No Abstract]   [Full Text] [Related]  

  • 38. Urological complications following use of recombinant human bone morphogenetic protein-2 in anterior lumbar interbody fusion: presented at the 2012 Joint Spine Section Meeting: clinical article.
    Lubelski D; Abdullah KG; Nowacki AS; Alvin MD; Steinmetz MP; Chakka S; Li Y; Gajewski N; Benzel EC; Mroz TE
    J Neurosurg Spine; 2013 Feb; 18(2):126-31. PubMed ID: 23231356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research.
    Carragee EJ; Baker RM; Benzel EC; Bigos SJ; Cheng I; Corbin TP; Deyo RA; Hurwitz EL; Jarvik JG; Kang JD; Lurie JD; Mroz TE; Oner FC; Peul WC; Rainville J; Ratliff JK; Rihn JA; Rothman DJ; Schoene ML; Spengler DM; Weiner BK
    Spine J; 2012 Oct; 12(10):877-80. PubMed ID: 23199819
    [No Abstract]   [Full Text] [Related]  

  • 40. Acknowledging the elephant in the room: conflict of interest in industry-sponsored clinical research.
    Hart RA
    Spine J; 2011 Aug; 11(8):703-4. PubMed ID: 21925414
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.